Option chain shows key data for Rallybio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Rallybio.

Rallybio (NASDAQ:RLYB) Stock, Option Chain

Rallybio

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AGEN

ALLR

ANET

APLD

BENF

CISS

CMAX

CPNG

DXYZ

EZGO

FRGE

GATO

GCTS

HRYU

HUBC

INTZ

LOVE

LXEH

LYEL

MGRM

MNDR

MOGU

MOTS

MRIN

NKLA

NRIX

NXPL

PXMD

RENT

RLYB

SAVA

SBFM

SERA

VERU

VIAO

Shares of  JPMorgan Chase &amp; Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.

Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Stock_Whisper_Index_Logo_6-copy

Biotech

Gaming

Restaurants

PUBM

RBLX

The weekly Benzinga Stock Whisper Index highlights five stocks that saw increased interest from readers. Here are this week&#39;s stocks to watch.

Benzinga&#39;s &#39;Stock Whisper&#39; Index: 5 Stocks Investors Secretly Monitor But Don&#39;t Talk About Yet

Pre-Market Outlook

DPRO

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

IONM

KZIA

ZPTA

Shares of  NextPlat Corp (NASDAQ: NXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year

Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket

Rallybio Corp

Press Releases

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Comments

Rallybio

Rallybio (RLYB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga